Dr Reddys Laboratories (RDY) Cash from Financing Activities (2009 - 2026)

Dr Reddys Laboratories has reported Cash from Financing Activities for 17 years, with the latest figure at -$75.2 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 434.8% year-over-year to -$75.2 million in Q2 2026; TTM through Jun 2026 was $28.1 million, a 72.05% decrease from a year earlier, with the FY2026 full-year figure at $88.0 million, down 60.36% from the prior year.
• Cash from Financing Activities was -$75.2 million for Q2 2026 at Dr Reddys Laboratories, down from $77.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $192.8 million in Q3 2024, with the low at -$154.9 million in Q3 2022.
• Average Cash from Financing Activities over 5 years is -$4.2 million, with a median of -$10.2 million recorded in 2025.
• The largest YoY upside for Cash from Financing Activities was 1149.78% in 2025 against a maximum downside of 1226.07% in 2025.
• Over 5 years, Cash from Financing Activities stood at $7.1 million in 2022, then surged by 793.36% to $63.4 million in 2023, then tumbled by 88.98% to $7.0 million in 2024, then surged by 1149.78% to $87.3 million in 2025, then plunged by 186.08% to -$75.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$75.2 million (Q2 2026), $77.0 million (Q1 2026), and $87.3 million (Q4 2025), per Business Quant data.